Alexander E. Sherman | AMiner学者主页

全面呈现 [Alexander E. Sherman] 的学术影响力

深度挖掘高质量成果与权威引用，让优秀看得见

研究兴趣

暂无数据

论文（22）

专利

基金项目

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

1The Role of ABCG2 and Other Stem Cell Markers in Tumorigenesis and Chemoresistance - an Analysis of Fresh Uterine Tumor Specimens

J. Chan,A. Sherman,J. Shin,T. Kiet,K. Blansit,L. Hu

Objective: The side-population (SP) of stemlike cancer cells have been implicated in tumorigenesis and drug resistance. We proposed to determine the pluripotency of these cells in uterine cancer.

2013Gynecologic Oncology（2013）

引用

AI阅读

2Brca Mutations and Advanced Stage Serous Epithelial Ovarian Cancer-Does the Type of Mutation Matter?

I. Lesnockl, J. Chan,T. Kiet,A. Sherman,B. Monk,R. Ruskin,D. Kapp,L. Chen,T. Krivak

Objective: To compare the survival of patients with serous epithelial ovarian cancer based on the type of BRCA mutation.

2012GYNECOLOGIC ONCOLOGY（2012）

引用

AI阅读

3The Use of Molecular Markers to Predict for Optimal Cytoreduction in Ovarian Cancer

K. Fuh,T. K. Kiet,L. Chen,R. A. Brooks,A. E. Sherman,D. S. Kapp,J. K. Chan

Objective: To determine the significance of specific gene markers associated with optimal cytoreductive surgery.

2012Gynecologic Oncology（2012）

引用

AI阅读

4Germline Versus Somatic BRCA Mutations: Analysis of the Cancer Genome Atlas Project in Patients with Advanced Stage Serous Epithelial Ovarian Cancer

J. Lesnock,T. Krivak,T. Kiet,A. Sherman,B. Monk,R. Ruskin,D. Kapp,L. Chen, J. Chen

Objective: To compare demographics, clinico-pathologic data, treatment response and survival of patients with serous epithelial ovarian cancer (EOC) with germline to somatic BRCA1 and BRCA2 (BRCA1/2) mutations.

2012Gynecologic Oncology（2012）引用：1

引用

AI阅读

5The Association of Vegf A, B, and C Expression in the Survival of Serous Ovarian Cancer Patients

T. K. Kiet,A. E. Sherman,B. J. Monk,D. S. Kapp,J. K. Chan

Objective: To determine the significance of VEGF expression on the survival of serous epithelial ovarian cancer patients.

2011GYNECOLOGIC ONCOLOGY（2011）引用：1

引用

AI阅读

6Chemotherapy Response and Survival in Serous Ovarian Cancer Patients with BRCA Mutations

J. K. Chan,T. K. Kiet,L. Chen,R. Ruskin,A. E. Sherman,B. J. Monk,D. S. Kapp,T. C. Krivak

Objective: To compare the demographic, clinico-pathologic, treatment response, and survival of patients with BRCA (germline and somatic) mutations.

2011Gynecologic Oncology引用：1

引用

AI阅读

7Targeting Mir-21 to Reverse Platinum Resistance in Ovarian Cancer

T. K. Kiet,A. E. Sherman,C. Melton,L. Hu,G. Wong,C. Earle,L. Y. W. Bourguignon,R. Blelloch,J. K. Chan

Objective: To investigate the role of miR-21 pathway in platinum resistance ovarian cancer.

2011GYNECOLOGIC ONCOLOGY（2011）

引用

AI阅读

8MicroRNA As a Novel Predictor of Response to Bevacizumab in Recurrent Serous Ovarian Cancer: an Analysis of the Cancer Genome Atlas

J. Chan,T. Kiet,A. Sherman,K. Fuh,S. Ueda,R. Brooks,D. Kapp,L. Chen,B. Monk

Objective: The aim of this study was to determine the association of miRNA expression and response to bevacizumab with survival in recurrent serous ovarian cancer.

2011Gynecologic Oncology（2011）引用：6

引用

AI阅读

9Differential Microrna Expression in Cis-Platinum-Resistant Versus -Sensitive Ovarian Cancer Cell Lines

A. Sherman,L. Hu,C. Melton,D. Kapp,J. Chan

Objective: The objective of this study was to determine the association of differential microRNA expression and cis-platinum-resistant versus -sensitive ovarian cancer.

2011GYNECOLOGIC ONCOLOGY（2011）

引用

AI阅读

10Factors Associated with Hospice Use in Ovarian Cancer

C. Casey,H. Deshmukh,A. Sherman,L. Chen,J. Chan

Objective: The purpose of this study was to determine the factors and trends in hospice use in patients with ovarian cancer in the Medicare population.

2011Gynecologic Oncology（2011）

引用

AI阅读

11Germline Vs. Somatic Brca Mutations and Response to Chemotherapy and Outcomes in Serous Ovarian Cancer

J. K. Chan,T. K. Kiet,L. Chen,R. Ruskin,A. E. Sherman,B. J. Monk,D. S. Kapp,T. C. Krivak

Objective: To differentiate the demographic, clinico-pathologic factors and survival of serous ovarian cancer patients with germline vs. somatic BRCA mutations.

2011GYNECOLOGIC ONCOLOGY（2011）

引用

AI阅读

12Preserving ovaries in young women with early-stage cervical adenocarcinoma: Is it safe?

K. Fuh,A. Sherman, A. Han,D. Kapp,L. Chen,J. Chan

2010GYNECOLOGIC ONCOLOGY（2010）

引用

AI阅读

13Institutional factors associated with high research productivity: A survey of academic gynecologic oncologists

J. Cohen,A. Sherman,P. O'Sullivan,D. Kapp,K. Osann,L. Chen,J. Chan

2010GYNECOLOGIC ONCOLOGY（2010）

引用

AI阅读

14The association of gynecologic oncology training program characteristics and research productivity: The fellows' perspective

J. Cohen,A. Sherman,P. O'Sullivan,D. Kapp,K. Osann,L. Chen,J. Chan

2010GYNECOLOGIC ONCOLOGY（2010）

引用

AI阅读

15Fertility preservation in early-stage borderline tumors

K. Fuh,A. Sherman, C. Nguyen, T. Macrae,L. Chen,D. Kapp,J. Chan

2010GYNECOLOGIC ONCOLOGY（2010）

引用

AI阅读

16Factors Associated with Successful Fda Approval after A Positive Phase Iii Clinical Trial Using Targeted Anticancer Agents

J. Chan,M. Loring,A. Sherman,T. Nguyen, C. Chen,J. Tan,K. Osann,J. Lai,D. Kapp, B. Monk

2010GYNECOLOGIC ONCOLOGY（2010）引用：23

引用

AI阅读

17Characteristics of fellowship programs more likely to produce academic gynecologic oncologists

J. Cohen,A. Sherman,P. O'Sullivan,D. Kapp,K. Osann,L. Chen,J. Chan

2010GYNECOLOGIC ONCOLOGY（2010）

引用

AI阅读

18The potential benefit of the extent of lymphadenectomy in corpus cancer after adjusting for chemotherapy, radiation and hospital characteristics in the medicare population

J. Chan,H. Deshmukh,R. Zhang,X. Yu,K. Osann,A. Sherman,A. Husain,L. Chen,D. Kapp

2010GYNECOLOGIC ONCOLOGY（2010）

引用

AI阅读

19Randomized phase II studies on targeted agents in cancers: What characteristics predict for success in subsequent phase III trials

J. Chan, T. Lu,A. Sherman,T. Nguyen,S. Ueda,C. Stave,J. Tan,D. Kapp,D. Sargent

2010GYNECOLOGIC ONCOLOGY（2010）

引用

AI阅读

20Ovarian cancer websites: How to discern between quality and popularity

J. Chapman,A. Sherman,J. Chan

2010GYNECOLOGIC ONCOLOGY（2010）

引用

AI阅读

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

Daniel Kapp合作论文数Department of Radiation Oncology, School of Medicine, Stanford University16

J. Chan合作论文数15

Lee-May Chen合作论文数Division of Gynecologic Oncology, Department of Obstetrics, Gynecology & Reproductive Sciences, School of Medicine, University of California San Francisco12

Bradley Monk合作论文数Division of Gynecologic Oncology, College of Medicine, University of Arizona;Florida Cancer Specialists & Research Institute;Creighton University8

Kathryn E. Osann合作论文数School of Medicine, University of California, Irvine7

O'Sullivan Patricia S合作论文数3

Long Chen合作论文数3

Harshal Deshmukh合作论文数Oklahoma Medical Research Foundation3

T. Nguyen合作论文数2

D. S. Kapp合作论文数2

Xinhua Yu合作论文数Univ Memphis, Sch Publ Hlth, Div Epidemiol Biostat & Environm Hlth, Memphis, TN 38152 USA2

Tan Judy Y合作论文数Center for AIDS Prevention Studies, University of California San Francisco2

R. Zhang合作论文数2

Stefanie M. Ueda合作论文数2

Thomas C. Krivak合作论文数2

Collin Melton合作论文数The Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California San Francisco2

John Chan合作论文数School of Medicine, University of California, San Francisco1

T. Krivak合作论文数1

J. Lai合作论文数1

Christopher Stave合作论文数Lane Medical Library, Stanford University School of Medicine1

Krivak Thomas C合作论文数1

Wong Gabriel合作论文数1

Lesnock Jamie L合作论文数1

Lilly Bourguignon合作论文数Department of Medicine, University of California, San Francisco1

Earle Christine合作论文数1

Kevin Blansit合作论文数Palo Alto Medical Foundation Research Institute;Fielding School of Public Health, UCLA;Fielding School of Public Health, Palo Alto Medical Foundation Research Institute1

Loring Megan合作论文数1

Blelloch Robert合作论文数Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, Univ Calif San Francisco1

C. Casey合作论文数1

Daniel James Sargent合作论文数Westfalia Fruit1

Rebecca A. Brooks合作论文数1

相似学者

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn